USHER III INITIATIVE INC has a total of 38 patent applications. It decreased the IP activity by 33.0%. Its first patent ever was published in 2012. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are BEIJING COLLAB PHARMA CO LTD, J PHARMA CO LTD and FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | Australia | 4 | |
#3 | Canada | 4 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Israel | 4 | |
#6 | South Africa | 4 | |
#7 | Hong Kong | 3 | |
#8 | WIPO (World Intellectual Property Organization) | 3 | |
#9 | Hungary | 2 | |
#10 | Japan | 1 | |
#11 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Owens Andrew Pate | 23 |
#2 | Lock Christopher James | 23 |
#3 | Malagu Karine Fabienne | 23 |
#4 | Esmieu William Rameshchandra Krishna | 21 |
#5 | Burli Roland Werner | 16 |
#6 | Harte William Edward | 16 |
#7 | Bürli Roland Werner | 7 |
#8 | Harte William E | 7 |
#9 | Saperstein David | 6 |
#10 | Karine Fabienne Malagu | 3 |
Publication | Filing date | Title |
---|---|---|
CA2986785A1 | Methods of treating or preventing a proteopathy | |
AU2013334139A1 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | |
CA2889537A1 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
US2014121197A1 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
AU2012249801A1 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome |